Média

Onxeo announces development of Beleodaq® oral formulation opening new opportunities for its HDAC inhibitor // DANISH TRANSLATION: Onxeo offentliggør udviklingen af en oral formulering af Beleodaq®, som åbner nye muligheder for selskabets HDAC-hæmmer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq®  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the first set of positive results from a preclinical pharmacokinetic (PK)…read more →

Publication of 2015 Reference Document // DANISH TRANSLATION: Offentliggørelse af Reference Document for 2015

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the publication of the Company’s 2015 Reference Document. The 2015 Reference Document, registered with the French Market Authorities (Autorité des Marchés Financiers) on April 29, 2016, is available to the…read more →

Onxeo First Quarter 2016 Financial Information and Business Update // DANISH TRANSLATION: Onxeo informerer om sine resultater og forretningsmæssige tiltag i 1. kvartal 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today provided an update on financial results and major milestones achieved during the first quarter of 2016, ending March…read more →

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment // DANISH TRANSLATION: Endelige data fra mekanistisk studie med Livatag® viser foretrukken affinitet for leveren, hvilket understøtter brugen til behandling af fremskreden HCC

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today reported the final data from a study aiming to confirm the mechanism…read more →

Passing on Onxeo’s Extraordinary and Ordinary General Meeting // DANISH TRANSLATION: Forløb af Onxeos ekstraordinære og ordinære generalforsamling

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that the Extraordinary and Ordinary General Meeting, held at the company’s headquarters in Paris, France on April 6, 2016, adopted all of the resolutions recommended by the Board of Directors….read more →

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC // DANISH TRANSLATION: Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III…read more →

Onxeo announces closing of DNA Therapeutics acquisition // DANISH TRANSLATION: Onxeo gennemfører opkøbet af DNA Therapeutics

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has completed the acquisition of DNA Therapeutics and its signal-interfering DNA (siDNA) repair technology and lead product…read more →